Neoadjuvant chemotherapy with non-pegylated liposomal doxorubicin, docetaxel and trastuzumab in HER-2/neu overexpressing breast cancer

被引：0
|
作者：
Schippinger, Walter [1 ]
Lileg, Brigitte [1 ]
Ploner, Ferdinand [1 ]
Weitzer, Werner [1 ]
Bauemhofer, Thomas [1 ]
Samonigg, Hellmut [1 ]
机构：
[1] Graz Univ, Graz, Austria
来源：
ANNALS OF ONCOLOGY | 2007年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：166 / 166
页数：1
相关论文
共 50 条
  • [1] Trastuzumab, non-pegylated liposomal-encapsulated doxorubicin and paclitaxel in the neoadjuvant setting of HER-2 positive breast cancer
    Moisés Uriarte-Pinto
    Ángel Escolano-Pueyo
    Vicente Gimeno-Ballester
    Oihana Pascual-Martínez
    María Reyes Abad-Sazatornil
    María José Agustín-Ferrández
    International Journal of Clinical Pharmacy, 2016, 38 : 446 - 453
  • [2] Trastuzumab, non-pegylated liposomal-encapsulated doxorubicin and paclitaxel in the neoadjuvant setting of HER-2 positive breast cancer
    Uriarte-Pinto, Moises
    Escolano-Pueyo, Angel
    Gimeno-Ballester, Vicente
    Pascual-Martinez, Oihana
    Reyes Abad-Sazatornil, Maria
    Jose Agustin-Ferrandez, Maria
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2016, 38 (02) : 446 - 453
  • [3] Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: A multicenter phase II trial
    Chia, Stephen
    Clemons, Mark
    Martin, Lee-Ann
    Rodgers, Angela
    Gelmon, Karen
    Pond, Gregory R.
    Panasci, Lawrence
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 2773 - 2778
  • [4] Liposomal doxorubicin in combination with trastuzumab and docetaxel as first line chemotherapy in HER-2 metastatic breast cancer patients
    Bighin, C.
    Puglisi, F.
    Cavazzini, G.
    Olmeo, N.
    Colucci, G.
    Garrone, O.
    Paccagnella, A.
    Labianca, R.
    Crino, L.
    Simoncini, E.
    Manzione, L.
    Nardi, M.
    Cortesi, E.
    Venturini, M.
    ANNALS OF ONCOLOGY, 2005, 16 : 9 - 9
  • [5] Non-Pegylated Liposomal Doxorubicin-Cyclophosphamide in Sequential Regimens with Taxanes as Neoadjuvant Chemotherapy in Breast Cancer Patients
    Vici, Patrizia
    Pizzuti, Laura
    Gamucci, Teresa
    Sergi, Domenico
    Conti, Francesca
    Zampa, Germano
    Del Medico, Pietro
    De Vita, Roy
    Pozzi, Marcello
    Botti, Claudio
    Di Filippo, Simona
    Tomao, Federica
    Sperduti, Isabella
    Di Lauro, Luigi
    JOURNAL OF CANCER, 2014, 5 (06): : 398 - 405
  • [6] Longterm survival benefit of neoadjuvant liposomal doxorubicin, docetaxel, and trastuzumab in HER2-overexpressing breast cancer: A retrospective and multicenter analysis.
    Brunner, Christine
    Wieser, Verena
    Jaeger, Thomas
    Lang, Alois
    Stoger, Herbert
    Suppan, Christoph
    Goebel, Georg
    Soleiman, Afschin
    Egle, Daniel
    Marth, Christian
    Hubalek, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [7] Cardiac safety and efficacy of concomitant liposomal doxorubicin, docetaxel, and trastuzumab as neoadjuvant therapy in HER2-overexpressing breast cancer: A retrospective analysis
    Brunner, Christine
    Jaeger, Thomas
    Suppan, Christoph
    Mueller-Holzner, Elisabeth
    Jasarevic, Zerina
    Balic, Marija
    Goebel, Georg
    Marth, Christian
    Stoeger, Herbert
    Samonigg, Hellmut
    Hubalek, Michael
    Lang, Alois
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [8] Neoadjuvant non-pegylated liposomal doxorubicin plus paclitaxel, trastuzumab and pertuzumab in patients with HER2+breast cancer - Final results of the SOLTI OPTI-HER HEART study
    Gavila, J.
    Perez-Garcia, J.
    Calvo, I.
    Ciruelos, E.
    Munoz, M.
    Virizuela, J. A.
    Ruiz, I.
    Andres, R.
    Morales, S.
    Perello, A.
    Sanchez, P.
    Garcia-Saenz, J. A.
    Quero Guillen, J. C.
    Gonzalez-Santiago, S.
    Garau Llinas, I.
    Gonzalez-Martin, A.
    Sanchez de Ibarguen, B. Cantos
    Zaragoza, K.
    de la Pena, L.
    Llombart-Cussac, A.
    Oliveira, M.
    CANCER RESEARCH, 2017, 77
  • [9] Pegylated Liposomal Doxorubicin, Docetaxel, and Trastuzumab as Neoadjuvant Treatment for HER2-Positive Breast Cancer Patients: A Phase II and Biomarker Study
    Wang, Haoqi
    Li, Yuntao
    Qi, Yixin
    Zhao, Erbao
    Kong, Xiangshun
    Yang, Chao
    Yang, Qiqi
    Zhang, Chengyuan
    Liu, Yueping
    Song, Zhenchuan
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [10] Adjuvant/neoadjuvant trastuzumab therapy in women with HER-2/neu-overexpressing breast cancer: A systematic review
    Madarnas, Yolanda
    Trudeau, Maureen
    Franek, Jacob A.
    McCready, David
    Pritchard, Kathleen I.
    Messersmith, Hans
    CANCER TREATMENT REVIEWS, 2008, 34 (06) : 539 - 557
12345